Solid Biosciences Inc. (SLDB) Investor Relations Documents

Solid Biosciences Inc. (SLDB) investor relations documents from the company's IR site: 11 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-06	Press release	Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-06-01	Press release	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01	Press release	Solid Biosciences to Participate at Upcoming Investor Conferences
2026-05-12	Press release	Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-07	Press release	Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscu
2026-05-01	Press release	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-30	Press release	Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Thera
2026-04-28	Press release	Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duch
2026-04-07	Press release	Solid Biosciences to Participate at Upcoming Investor Conferences
2026-03-19	Press release	Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
	Press release	Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to

SLDB overview · SLDB earnings · SLDB financials · SLDB KPIs · SLDB ownership · SLDB peers · SLDB filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.